Filing Flows › Spero Therapeutics (SPRO) › Q4 2025 › vs Q3 2025
Spero Therapeutics (SPRO) Q4 2025 vs Q3 2025 (quarter over quarter)
Spero Therapeutics's revenue rose $35.9M (+659%) from $5.4M in Q3 2025 to $41.3M in Q4 2025. Operating margin 76.0% against -145.5% (+221.5 pts).
Spero Therapeutics, Q4 2025: revenue $41.3M (+174% year over year), operating margin 76.0%, net earnings $31.5M, operating cash flow −$8.4M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q4 2025 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 76.0% | -145.5% | +221.5 pts |
| Net margin | 76.3% | -135.6% | +212.0 pts |
Every line
| Line | Q4 2025 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $41.3M | $5.4M | $35.9M | +659% |
| Other income, net | $376K | $534K | −$158K | -30% |
| Operating profit | $31.4M | −$7.9M | $39.3M | — |
| Costs & expenses | $9.9M | $13.4M | −$3.5M | -26% |
| Pre-tax earnings | $31.8M | −$7.4M | $39.2M | — |
| Research & development | $5.6M | $8.6M | −$3.0M | -35% |
| General & admin | $4.3M | $4.2M | $126K | +3% |
| Net earnings | $31.5M | −$7.4M | $38.9M | — |
| Income tax | $261K | $0 | $261K | — |
| Operating cash sources | $40.9M | −$23.8M | $64.6M | — |
| Share-based compensation | $1.0M | $1.0M | −$41K | -4% |
| Cash used in operations | $8.4M | −$17.4M | $25.8M | — |
| Working capital & other | $40.9M | −$23.8M | $64.6M | — |
Questions
How much did Spero Therapeutics's revenue grow quarter over quarter in Q4 2025?
Spero Therapeutics's revenue rose $35.9M (+659%) from $5.4M in Q3 2025 to $41.3M in Q4 2025. Operating margin 76.0% against -145.5% (+221.5 pts).